The Three Paradoxes Holding Back Alzheimer’s Disease Clinical Trials, and What To Do About Them
In Alzheimer’s disease research, things that should make clinical trials easier are introducing new challenges. Our experts explore three paradoxes holding back progress and how sponsors are working to solve them.
Alzheimer’s disease clinical trials are facing a complex and evolving reality. Despite new diagnostics, earlier intervention strategies and broader trial access, operational barriers are preventing sponsors from realizing the full potential of innovation.
In this article, Syneos Health experts unpack three key paradoxes holding Alzheimer’s disease trials back—and offer forward-looking strategies for overcoming them, including :
- Why more diagnoses aren’t leading to easier recruitment, and how to find patients
- How earlier treatment interventions may weaken trial signals—and what to do about it
- Why decentralization is a double-edged sword—and how to maximize access while minimizing site burden
Fill out the form below to understand how more agile design, planning and operations can help sponsors move beyond roadblocks and into meaningful progress.
Related Content
Looking for exclusive insight?
